Pressurized Oxygen Chambers Are Being Tested as a New Fibromyalgia Treatment — Here's What the HOTFy Trial Is Investigating

For decades, fibromyalgia has occupied an uncomfortable space in medicine — widely experienced, poorly understood, and frustratingly difficult to treat. Millions of people live with its signature constellation of widespread pain, crushing fatigue, disrupted sleep, and neuropsychiatric symptoms like anxiety, depression, and cognitive fog. Despite its prevalence, no single treatment reliably addresses the full picture. That is partly because most conventional therapies are aimed at symptom management, not at the underlying biology driving the condition. A new randomized clinical trial called HOTFy is attempting something more ambitious: using pressurized oxygen chambers to target the neurological dysfunction at fibromyalgia's core.

Why Fibromyalgia Is a Brain and Nervous System Problem, Not Just a Muscle Problem

One of the most persistent misconceptions about fibromyalgia is that the pain lives in the muscles and soft tissues — that something structural is broken, inflamed, or torn. Research has shifted that understanding significantly. Fibromyalgia is now classified as a central sensitization disorder, which means the central nervous system itself has become dysregulated.

In central sensitization, the brain and spinal cord essentially turn up the volume on pain signals. Stimuli that would be harmless — a light touch, mild temperature changes, even sound — can register as painful. This is why fibromyalgia is described as 'polysymptomatic': the problem isn't isolated to one body part, but reflects a system-wide shift in how the nervous system processes and responds to input. The condition involves widespread pain, yes, but also fatigue, sleep architecture disruptions, mood dysregulation, and cognitive impairment, because these all share the same neurological infrastructure.

The Science Behind Putting Fibromyalgia Patients in a Pressurized Oxygen Chamber

Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen inside a sealed chamber pressurized to levels higher than normal atmospheric pressure. This forces significantly more oxygen into the bloodstream and tissues than regular breathing allows, including into areas of the body where oxygen delivery is typically limited.

HBOT has an established track record in wound healing and treating conditions like carbon monoxide poisoning and decompression sickness. But researchers are increasingly interested in its effects on the brain and nervous system. According to the HOTFy trial framework, HBOT is thought to act through three distinct biological pathways particularly relevant to fibromyalgia: modulating neuroinflammation, improving mitochondrial function, and promoting neuroplasticity.

Neuroinflammation — low-grade inflammation in the brain and central nervous system — is increasingly recognized as a driver of central sensitization. Mitochondrial dysfunction, which impairs the tiny structures inside cells that produce energy, contributes to the fatigue and cognitive impairment that fibromyalgia patients consistently report. Neuroplasticity refers to the brain's ability to reorganize and repair itself; in chronic pain conditions, this capacity may be blunted. HBOT is proposed to address all three mechanisms simultaneously, which helps explain why researchers believe it may produce both pain-relieving and functional benefits.

How the HOTFy Trial Is Structured — And Why the Randomization Matters

The HOTFy study is a randomized clinical trial, the design considered most rigorous in medical research. Randomization means participants are assigned by chance to either receive HBOT or a control condition, which removes the risk that researchers unconsciously place people with milder or more severe fibromyalgia into one group over another. This design is essential for determining whether any improvements seen in HBOT recipients are genuinely caused by the treatment, rather than by natural fluctuation in symptoms or the psychological effect of receiving a novel intervention.

The trial's focus on fibromyalgia is also notable because HBOT research in this population is still relatively early-stage. While some prior uncontrolled or smaller studies have suggested that HBOT may reduce fibromyalgia pain and improve quality of life, a well-designed randomized trial is necessary before the treatment can be considered a validated option. The HOTFy trial is designed to provide that higher level of evidence.

What This Research Means for People Living With Fibromyalgia

If you have fibromyalgia, you may already be familiar with the frustrating reality that most available treatments provide partial relief at best. Medications approved for fibromyalgia — including certain antidepressants and nerve-calming drugs — are effective for some people but leave many others with inadequate symptom control. Exercise and psychological therapies have solid evidence behind them, but they do not work for everyone, and accessing them consistently can be difficult.

The HOTFy trial matters because it is investigating whether a treatment that works at the neurobiological level — not just masking pain signals, but potentially altering the dysfunctional processes causing them — can produce meaningful improvements across multiple symptom domains at once. That kind of broad-spectrum effect would be genuinely novel for fibromyalgia care. However, it is important to understand that this is an active clinical trial. Results have not yet been published, and HBOT is not currently an established or widely available treatment for fibromyalgia. You should not seek out hyperbaric oxygen chambers independently based on this research alone.

What this trial does represent is a meaningful expansion of research into fibromyalgia's neurological foundations. As understanding of central sensitization deepens, trials like HOTFy may help establish whether interventions that directly address brain function can become part of a more comprehensive, evidence-based treatment approach.